James Chiu, MD
Psychiatry · Sioux Falls, SDNPI 1124347265
Payments from drug & device makers
Across 2,695 payments — averaging $617.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$266K
- Alkermes, Inc.$243K
- AbbVie$229K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$217K
- Johnson & Johnson$191K
- Axsome Therapeutics, Inc.$174K
- plus $344K from 24 others
What the payments were for
- Consulting fees$74,9425%
- Speaking & faculty fees$1,369,57583%
- Travel & lodging$170,87010%
- Food & beverage$42,1193%
- Education$5740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 403 | $265,748 |
| Alkermes, Inc. | 418 | $243,096 |
| AbbVie(2 entities) | 464 | $229,264 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 283 | $217,189 |
| Johnson & Johnson | 328 | $191,291 |
| Axsome Therapeutics, Inc. | 198 | $173,741 |
| Teva Pharmaceuticals USA, Inc. | 181 | $150,082 |
| E.r. Squibb & Sons, L.L.C. | 133 | $99,246 |
| Vanda Pharmaceuticals Inc. | 151 | $79,262 |
| Idorsia Pharmaceuticals US Inc | 33 | $12,441 |
| Neuronetics, Inc. | 7 | $1,020 |
| Supernus Pharmaceuticals, Inc. | 10 | $284 |
| Neurocrine Biosciences, Inc. | 16 | $266 |
| Lundbeck LLC | 17 | $246 |
| Janssen Scientific Affairs, LLC | 2 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $116 |
| Almatica Pharma LLC | 6 | $98 |
| Merck | 5 | $88 |
| Acadia Pharmaceuticals Inc | 5 | $80 |
| Tris Pharma Inc | 4 | $69 |
| Avanir Pharmaceuticals, Inc. | 4 | $54 |
| Sage Therapeutics, LLC | 3 | $49 |
| Corium, LLC | 7 | $49 |
| Ironshore Pharmaceuticals Inc. | 3 | $47 |
| Noven Therapeutics, LLC | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$596,844
- LYBALVI$329,794
- VRAYLAR$224,467
- REXULTI$223,062
- CAPLYTA$213,272
- Auvelity$170,844
- ARISTADA INITIO$149,211
- UZEDY$147,079
- COBENFY$96,601
- INVEGA TRINZA$93,964
- INVEGA SUSTENNA$93,840
- SPRAVATO$93,042
- Fanapt$77,075
- ABILIFY MAINTENA$38,850
- ABILIFY ASIMTUFII$36,310
- QUVIVIQ$11,959
- NEUROSTAR TMS THERAPY$884
- VIIBRYD$200
How this compares
$1,664,080 in reported general payments places this provider in the 95th percentile of 79 psychiatry providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 110 | $351,008 |
| AristadaAripiprazole Lauroxil | 65 | $227,613 |
| Invega TrinzaPaliperidone Palmitate | 19 | $166,221 |
| Abilify MaintenaAripiprazole | 53 | $149,155 |
| VraylarCariprazine Hcl | 75 | $105,623 |
| CaplytaLumateperone Tosylate | 78 | $103,829 |
| UzedyRisperidone | 16 | $82,141 |
| LybalviOlanzapine/Samidorphan Malate | 52 | $82,047 |
| SpravatoEsketamine Hcl | 37 | $46,598 |
| Clozapine | 429 | $24,250 |
| TrintellixVortioxetine Hydrobromide | 39 | $19,567 |
| QuviviqDaridorexant Hcl | 38 | $17,760 |
| AuvelityDextromethorphan Hbr/Bupropion | 15 | $15,374 |
| Divalproex Sodium ErDivalproex Sodium | 92 | $7,058 |
| Lurasidone Hcl | 43 | $5,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Spravato | $191,291 | $563,827166 claims |
| Alkermes, Inc.Aristada, Lybalvi | $243,096 | $309,660117 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $265,748 | $149,15553 claims |
| AbbVieVraylar | $229,264 | $105,62375 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $217,189 | $103,82978 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $150,082 | $82,14116 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $116 | $19,56739 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $12,441 | $17,76038 claims |
| Axsome Therapeutics, Inc.Auvelity | $173,741 | $15,37415 claims |
| Almatica Pharma LLCSertraline Hcl | $98 | $1,730224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 psychiatry providers in South Dakota.
Other psychiatry in Sioux Falls
- Hari KannanSioux Falls$913K
- Rajesh SinghSioux Falls$393K
- Anthony VacaSioux Falls$15K
- Mackenzie MertzSioux Falls$4K
- Georgiana NussSioux Falls$4K
- Sandra Peynado RojasSioux Falls$3K
- David ErmerSioux Falls$3K
- Clay PavlisSioux Falls$2K
- William FullerSioux Falls$2K
- Xiaofan LiSioux Falls$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.